var title_f9_58_10144="Aqueductal stenosis due to a tectal lesion";
var content_f9_58_10144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aqueductal stenosis due to a tectal lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T1 weighted magnetic resonance imaging (MRI) showing aqueductal stenosis. The hydrocephalus was treated with a third ventriculostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Abilash Haridas and Tadanori Tomita.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10144=[""].join("\n");
var outline_f9_58_10144=null;
var title_f9_58_10145="Insulin injection PI";
var content_f9_58_10145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    How to give an insulin shot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <ol>",
"     <li>",
"      Pinch up some skin and quickly insert the needle at a 90&deg; angle (or whatever angle your doctor or nurse tells you). Keep the skin pinched to avoid having the insulin go into the muscle.",
"     </li>",
"     <li>",
"      Push the plunger down all the way. Hold the syringe and needle in place for 5 seconds.",
"     </li>",
"     <li>",
"      Let go of the pinched skin and remove the needle from the skin. If you see blood or clear fluid (insulin) where the needle went in, press on the area for 5 to 8 seconds, but do not rub.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10145=[""].join("\n");
var outline_f9_58_10145=null;
var title_f9_58_10146="Brain MRI age 10 years juvenile Alexander disease";
var content_f9_58_10146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Late brain MRI of a patient with presumed juvenile Alexander disease, obtained at the age of 10 years",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is extensive white matter  involvement with frontal preponderance  (A). The basal ganglia are dark and atrophic on T2-weighted images (A). A thin  periventricular rim of low signal intensity is  just visible (arrows, A). After contrast administration, enhancement of the entire  cerebellar surface and dentate nucleus is  seen (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: van der Knaap, MS, Naidu, S, Breiter, SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy;2001 American Society of Neuroradiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10146=[""].join("\n");
var outline_f9_58_10146=null;
var title_f9_58_10147="Contralateral breast management";
var content_f9_58_10147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Contralateral reduction mammoplasty for symmetry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following right mastectomy, the patient had an immediate right breast reconstruction with an expander followed by an anatomic saline implant. Reduction mammoplasty of the contralateral side was performed to restore symmetry. Left panel: preoperative appearance; right panel: postoperative appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge de la Pedraja, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10147=[""].join("\n");
var outline_f9_58_10147=null;
var title_f9_58_10148="Nonbleeding esophageal varices";
var content_f9_58_10148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87066%7EGAST%2F87067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87066%7EGAST%2F87067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal varices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic images from a patient with esophageal varices. Varices may or may not have stigmata of bleeding. These varices are large but do not have clear stigmata of bleeding, such as red wale signs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actively bleeding esophageal varix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an actively bleeding esophageal varix. The varix was banded successfully, and the bleeding stopped.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10148=[""].join("\n");
var outline_f9_58_10148=null;
var title_f9_58_10149="Methsuximide: Pediatric drug information";
var content_f9_58_10149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methsuximide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/54/43876?source=see_link\">",
"    see \"Methsuximide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/29/15829?source=see_link\">",
"    see \"Methsuximide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Celontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Succinimide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/54/43876?source=see_link\">",
"      see \"Methsuximide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 10-15 mg/kg/day in 3-4 divided doses; increase weekly up to maximum of 30 mg/kg/day; mean dose required:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;30 kg: 20 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;30 kg: 14 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 300 mg/day for the first week; may increase by 300 mg/day at weekly intervals up to 1.2 g in 2-4 divided doses/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Celontin&reg;: 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10916633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229201.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229201.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); protect from light, moisture, and excessive  heat 40&deg;C (104&deg;F);",
"     <b>",
"      Note:",
"     </b>",
"     Methsuximide has a relatively low melting temperature (124&deg;F); do not store in conditions that promote high temperatures (eg, in a closed vehicle)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of refractory absence (petit mal) seizures (FDA approved in children and adults); useful adjunct in refractory, partial complex (psychomotor) seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methsuximide may be confused with ethosuximide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hyperemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressiveness, ataxia, confusion, depression, dizziness, drowsiness, hallucinations (auditory), headache, hypochondriacal behavior, insomnia, irritability, mental instability, mental slowness, nervousness, psychosis, suicidal behavior",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, epigastric pain, nausea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria (microscopic), proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, monocytosis, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, periorbital edema, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hiccups, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methsuximide, other succinimides, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal disease. Avoid abrupt withdrawal (may precipitate absence status). When used alone, methsuximide may increase tonic-clonic seizures in patients with mixed seizure disorders; methsuximide must be used in combination with other anticonvulsants in patients with both absence and tonic-clonic seizures. May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood dyscrasias (sometimes fatal) have been reported (monitor hematologic function periodically or if signs/symptoms of infection develop); SLE has been reported with the use of succinimides",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED-treated patients compared to 0.24% in patients receiving placebo); increased risk was observed as early as one week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs, informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7793124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Patients exposed to methsuximide during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver enzymes, urinalysis; measure trough serum levels for efficacy and 3-hour postdose concentrations for toxicity; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1053921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measure N-desmethylmethsuximide concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: 10-40 mcg/mL (SI: 53-212 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;40 mcg/mL (SI: &gt;212 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the seizure threshold and suppresses paroxysmal spike-and-wave pattern in absence seizures; depresses nerve transmission in the motor cortex",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly demethylated in the liver to N-desmethylmethsuximide (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desmethylmethsuximide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 28-80 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% in urine as unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/29/15829?source=see_link\">",
"      see \"Methsuximide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Do not discontinue abruptly (seizures may occur). Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm. Notify physician if sore throat or fever develop. Report worsening of seizure activity or loss of seizure control. Do not store capsules in conditions that promote high temperatures (eg, in closed cars or other vehicles), as medication may melt.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Miles MV, Tennison MB, and Greenwood RS, &ldquo;Pharmacokinetics of N-desmethylmethsuximide in Pediatric Patients,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(4 Pt 1):647-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10149/abstract-text/2926578/pubmed\" id=\"2926578\" target=\"_blank\">",
"        2926578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tennison MB, Greenwood RS, Miles MV, &ldquo;Methsuximide for Intractable Childhood Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(2):186-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10149/abstract-text/ 1987529 /pubmed\" id=\" 1987529 \" target=\"_blank\">",
"        1987529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12596 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-4F267068D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10149=[""].join("\n");
var outline_f9_58_10149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053918\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053911\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194846\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194831\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916633\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053923\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053914\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053922\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194878\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194877\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053926\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053910\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053909\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194869\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194839\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7793124\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053917\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053921\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053908\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053925\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053916\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/54/43876?source=related_link\">",
"      Methsuximide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/29/15829?source=related_link\">",
"      Methsuximide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_58_10150="Axillary artery anatomy";
var content_f9_58_10150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Axillary artery anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axillary artery is palpated within the axilla when the arm is abducted and externally rotated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10150=[""].join("\n");
var outline_f9_58_10150=null;
var title_f9_58_10151="Cetuximab: Drug information";
var content_f9_58_10151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cetuximab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/62/30692?source=see_link\">",
"    see \"Cetuximab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Erbitux&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F1995494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Erbitux&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Epidermal Growth Factor Receptor (EGFR) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with an H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist (eg, diphenhydramine) I.V. 30-60 minutes prior to the first dose; premedication for subsequent doses is based on clinical judgement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Colorectal cancer, metastatic, KRAS mutation-negative (wild-type):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial loading dose: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 60 minutes weekly until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If given in combination with FOLFIRI (irinotecan, fluorouracil, and leucovorin), complete cetuximab infusion 1 hour prior to FOLFIRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Head and neck cancer (squamous cell):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial loading dose: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 120 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     infused over 60 minutes weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If given in combination with radiation therapy, administer loading dose 1 week prior to initiation of radiation course; weekly maintenance dose should be completed 1 hour prior to radiation for the duration of radiation therapy (6-7 weeks). If given in combination with chemotherapy, administer loading dose on the day of initiation of platinum and fluorouracil-based chemotherapy, cetuximab infusion should be completed 1 hour prior to initiation of chemotherapy; weekly maintenance dose should be completed 1 hour prior to chemotherapy; continue until disease progression or unacceptable toxicity. Monotherapy weekly doses should be continued until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, advanced, biweekly administration (unlabeled dosing):",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 2 weeks (initial dose infused over 120 minutes, subsequent doses infused over 60 minutes) in combination with irinotecan (Pfeiffer, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC), EGFR-expressing, advanced (unlabeled use):",
"     </b>",
"     I.V.: Initial loading dose: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , followed by maintenance dose: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly in combination with cisplatin and vinorelbine for up to 6 cycles, then as monotherapy until disease progression or unacceptable toxicity (Pirker, 2009; Pirker, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Squamous cell skin cancer, unresectable (unlabeled use):",
"     </b>",
"     I.V.:  Initial loading dose: 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , followed by maintenance dose: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly until disease progression (Maubec, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F149034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infusion reactions, grade 1 or 2 and nonserious grade 3: Reduce the infusion rate by 50% and continue to use prophylactic antihistamines",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion reactions, severe: Immediately and permanently discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pulmonary toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute onset or worsening pulmonary symptoms: Hold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Interstitial lung disease: Permanently discontinue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Skin toxicity, mild-to-moderate: No dosage modification required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acneiform rash, severe (grade 3 or 4):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     First occurrence: Delay cetuximab infusion 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If improvement, continue at 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If no improvement, discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Second occurrence: Delay cetuximab infusion 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If improvement, continue at reduced dose of 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If no improvement, discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Third occurrence: Delay cetuximab infusion 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If improvement, continue at reduced dose of 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If no improvement, discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fourth occurrence: Discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose adjustments are not recommended for severe",
"     <b>",
"      radiation",
"     </b>",
"     dermatitis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Erbitux&reg;: 2 mg/mL (50 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F148998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer via I.V. infusion; loading dose over 2 hours, weekly maintenance dose over 1 hour. Do not administer as I.V. push or bolus. Do not shake or dilute. Administer via infusion pump or syringe pump. Following the infusion, an observation period (1 hour) is recommended; longer observation time (following an infusion reaction) may be required. Premedication with an H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist prior to the initial dose is recommended. The maximum infusion rate is 10 mg/minute. Administer through a low protein-binding 0.22 micrometer in-line filter. Use 0.9% NaCl to flush line at the end of infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For biweekly administration (unlabeled frequency and dose), the initial dose was infused over 120 minutes and subsequent doses infused over 60 minutes (Pfeiffer, 2007; Pfeiffer, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F148997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of",
"     <i>",
"      KRAS",
"     </i>",
"     mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (in combination with FOLFIRI [irinotecan, fluorouracil, and leucovorin] as first-line treatment, in combination with irinotecan [in patients refractory to irinotecan-based chemotherapy], or as a single agent in patients who have failed oxaliplatin and irinotecan based chemotherapy or who are intolerant to irinotecan);  treatment of squamous cell cancer of the head and neck (as a single agent for recurrent or metastatic disease after platinum-based chemotherapy failure; in combination with radiation therapy as initial treatment of locally or regionally advanced disease; in combination with platinum and fluorouracil-based chemotherapy as first-line treatment of locoregional or metastatic disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Cetuximab is not indicated for the treatment of",
"     <i>",
"      KRAS",
"     </i>",
"     mutation-positive colorectal cancer.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6825474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of EGFR-expressing advanced nonsmall cell lung cancer (NSCLC); treatment of unresectable squamous cell skin cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2110716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cetuximab may be confused with bevacizumab",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Except where noted, percentages reported for studies with cetuximab monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (91%), pain (59%), sensory neuropathy (45%; grades 3/4: 1%), headache (38%), insomnia (27%), fever (25%), confusion (18%), anxiety (14%), chills/rigors (16%), depression (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash/desquamation (95%; grades 3/4: 16%), acneiform rash (all studies: 76% to 88%; grades 3/4: 1% to 17%; onset: &le;14 days), dry skin (57%), pruritus (47%), nail changes (31%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypomagnesemia (all studies: 55%; grades 3/4: 6% to 17%), dehydration (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (64%), abdominal pain (59%), constipation (53%), diarrhea (42%), vomiting (37% to 40%), stomatitis (32%), xerostomia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (15%), arthralgia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (48% to 49%), cough (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (all studies: 13% to 44%; grades 3/4: 11%), infusion reaction (all studies: 15% to 21%; grades 3/4: 2% to 5%; 90% of severe reactions occurred with first infusion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiopulmonary arrest (2%; with radiation therapy; 3% with platinum/fluorouracil-based chemotherapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbance (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal failure (all studies: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Antibody formation (5%), sepsis (all studies: 1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; all studies): Abscess formation, arrhythmia, aseptic meningitis, blepharitis, cardiac arrest, cellulitis, cheilitis, conjunctivitis, hypertrichosis, hypotension, interstitial lung disease (occurred between the fourth and eleventh doses), keratitis, leukopenia, loss of consciousness, MI, pulmonary embolism, radiation dermatitis, shock, skin fissure, skin infection, ulcerative keratitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s U.S. product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Severe hypersensitivity to cetuximab or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F148986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiopulmonary arrest:",
"     <b>",
"      [U.S. Boxed Warning]: In patients with squamous cell head and neck cancer, cardiopulmonary arrest and/or sudden death has occurred in 2% of patients receiving radiation therapy in combination with cetuximab and in 3% of patients receiving combination chemotherapy (platinum and fluorouracil-based) with cetuximab. Closely monitor serum electrolytes (magnesium, potassium, calcium) during and after cetuximab treatment",
"     </b>",
"     (monitor for at least 8 weeks after treatment). Use with caution in patients with history of coronary artery disease, HF, and arrhythmias; fatalities have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity: Acneiform rash has been reported in 76% to 88% of patients (severe in 1% to 17%), usually developing within the first 2 weeks of therapy; may require dose modification; generally resolved after discontinuation in most patients, although persisted beyond 28 days in some patients. Monitor for dermatologic toxicity and corresponding infections. Acneiform rash should be treated with topical and/or oral antibiotics; topical corticosteroids are not recommended. In colorectal cancer, the presence of acneiform rash correlates with treatment response and prolonged survival (Cunningham, 2004). Other dermatologic toxicities, including dry skin, fissures, hypertrichosis, paronychial inflammation, and skin infections have been reported; related ocular toxicities (blepharitis, conjunctivitis, keratitis, ulcerative keratitis with decreased visual acuity) may also occur. Sunlight may exacerbate skin reactions (limit sun exposure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte abnormality: Hypomagnesemia is common (may be severe); the onset of electrolyte disturbance may occur within days to months after initiation of treatment; monitor magnesium, calcium, and potassium during treatment and for at least 8 weeks after completion. May require electrolyte replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions:",
"     <b>",
"      [U.S. Boxed Warning]: In clinical trials, serious infusion reactions have been reported in ~3% of patients; fatal outcome has been reported rarely (&lt;1 in 1000); interrupt infusion promptly and permanently discontinue for serious infusion reactions.",
"     </b>",
"     Reactions have included airway obstruction (bronchospasm, stridor, hoarseness), hypotension, loss of consciousness, shock, MI, and/or cardiac arrest. Premedicate with an I.V. H",
"     <sub>",
"      1",
"     </sub>",
"     antagonist 30-60 minutes prior to the first dose; premedication for subsequent doses is based on clinical judgement and with consideration of prior reaction to the initial infusion. The use of nebulized albuterol-based premedication to prevent infusion reaction has been reported (Tra, 2008). Approximately 90% of reactions occur with the first infusion despite the use of prophylactic antihistamines. Immediate treatment for anaphylactic/anaphylactoid reactions should be available during administration. The manufacturer recommends monitoring patients for at least 1 hour following completion of infusion, or longer if a reaction occurs. Mild-to-moderate infusion reactions (chills, fever, dyspnea) are managed by slowing the infusion rate (by 50%) and administering antihistamines. Patients with pre-existing IgE antibody against cetuximab (specific for galactose-&alpha;-1,3-galactose) are reported to have a higher incidence of severe hypersensitivity reaction. Severe hypersensitivity reaction has been reported more frequently in patients living in the middle south area of the United States, including North Carolina and Tennessee (Chung, 2008; O&rsquo;Neil, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Interstitial lung disease (ILD): Has been reported; use with caution in patients with pre-existing lung disease. Interrupt treatment for acute onset or worsening of pulmonary symptoms. Permanently discontinue with confirmed ILD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colorectal cancer/tumor",
"     <i>",
"      KRAS",
"     </i>",
"     mutation status: Cetuximab is only indicated for patients with EGFR-expressing,",
"     <i>",
"      KRAS",
"     </i>",
"     mutation-negative metastatic colorectal cancer. Determine",
"     <i>",
"      KRAS",
"     </i>",
"     mutation status prior to treatment (the therascreen",
"     <i>",
"      KRAS",
"     </i>",
"     RGQ PCR Kit is approved in the U.S. to determine",
"     <i>",
"      KRAS",
"     </i>",
"     gene mutation information). Patients with a codon 12 or 13 (exon 2)",
"     <i>",
"      KRAS",
"     </i>",
"     mutation are unlikely to benefit from EGFR inhibitor therapy and should not receive cetuximab treatment; cetuximab is not effective for",
"     <i>",
"      KRAS",
"     </i>",
"     mutation-positive colorectal cancer. Cetuximab is also reported to be ineffective in patients with",
"     <i>",
"      BRAF",
"     </i>",
"     V600E mutation (Di Nicolantonio, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; EGFR expression testing: In trials for colorectal cancer, evidence of EGFR expression was required, although the response rate did not correlate with either the percentage of cells positive for EGFR or the intensity of expression. EGFR expression has been detected in nearly all patients with head and neck cancer, therefore, laboratory evidence of EGFR expression is not necessary for head and neck cancers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination with cisplatin and radiation therapy: Safety has not been established when used in combination with radiation therapy",
"     <b>",
"      and",
"     </b>",
"     cisplatin; fatalities and serious cardiotoxicity, pneumonia or other adverse events have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anti-cetuximab antibodies: Non-neutralizing anti-cetuximab antibodies were detected in 5% of evaluable patients. Relationship between the appearance of antibodies and the safety or antitumor activity of the molecule is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In pregnant cynomolgus monkeys, cetuximab was detected in the amniotic fluid and in the serum of embryos. Although teratogenic effects were not observed in animal reproduction studies, increases in embryolethality and fetal loss were noted. It is not known whether cetuximab can cause fetal harm or affect reproductive capacity. Because cetuximab inhibits epidermal growth factor (EGF), a component of fetal development, adverse effects on pregnancy would be expected. Cetuximab should only be given to a pregnant woman if the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F149005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to discontinue cetuximab or discontinue breast-feeding should take into account the benefits of treatment to the mother. If breast-feeding is interrupted for cetuximab treatment, based on the half-life, breast-feeding should not be resumed for at least 60 days following the last cetuximab dose.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Erbitux Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/50 mL (50 mL): $611.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/100 mL (100 mL): $1222.70",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F148994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs during infusion and observe for at least 1 hour postinfusion. Patients developing dermatologic toxicities should be monitored for the development of complications. Periodic monitoring of serum magnesium, calcium, and potassium are recommended to continue over an interval consistent with the half-life (8 weeks); monitor closely (during and after treatment) for cetuximab plus radiation therapy.",
"     <i>",
"      KRAS",
"     </i>",
"     genotyping of tumor tissue in patients with colorectal cancer (the therascreen",
"     <i>",
"      KRAS",
"     </i>",
"     RGQ PCR Kit is approved in the U.S. to determine",
"     <i>",
"      KRAS",
"     </i>",
"     gene mutation status [codon 12 or 13]).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Erbitux (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F148985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recombinant human/mouse chimeric monoclonal antibody which binds specifically to the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands. Binding to the EGFR blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix metalloproteinase and vascular endothelial growth factor production. EGFR signal transduction results in",
"     <i>",
"      KRAS",
"     </i>",
"     wild-type activation; cells with",
"     <i>",
"      KRAS",
"     </i>",
"     mutations appear to be unaffected by EGFR inhibition.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~2-3 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~112 hours (range: 63-230 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allegra CJ, Jessup JM, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology Provisional Clinical Opinion: Testing for",
"      <i>",
"       KRAS",
"      </i>",
"      Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy, &rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(12):2091-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/19188670/pubmed\" id=\"19188670\" target=\"_blank\">",
"        19188670",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baselga J, &ldquo;The EGFR as a Target for Anticancer Therapy - Focus on Cetuximab,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2001, 37(Suppl 4):16-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bonner JA, Harari PM, Giralt J, et al, &ldquo;Radiotherapy Plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):567-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/16467544/pubmed\" id=\"16467544\" target=\"_blank\">",
"        16467544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chung CH, Mirakhur B, Chan E, et al, &ldquo;Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-alpha-1,3-galactose,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(11):1109-17",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/18337601/pubmed\" id=\"18337601\" target=\"_blank\">",
"        18337601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cunningham D, Humblet Y, Siena S, et al, &ldquo;Cetuximab Monotherapy and Cetuximab Plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(4):337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/15269313/pubmed\" id=\"15269313\" target=\"_blank\">",
"        15269313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Di Nicolantonio F, Martini M, Molinari F, et al, &ldquo;Wild-type BRAF is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(35):5705-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/19001320/pubmed\" id=\"19001320\" target=\"_blank\">",
"        19001320",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feinstein TM, Gibson MK, and Argiris A, &ldquo;Cetuximab-Induced Aseptic Meningitis,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2009, 20(9):1609-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/19643807/pubmed\" id=\"19643807\" target=\"_blank\">",
"        19643807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jonker DJ, O&rsquo;Callaghan CJ, Karapetis CS, et al, &ldquo;Cetuximab for the Treatment of Colorectal Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(20):2040-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/18003960/pubmed\" id=\"18003960\" target=\"_blank\">",
"        18003960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karapetis CS, Khambata-Ford S, Jonker DJ, et al, &ldquo;K-ras Mutations and Benefit From Cetuximab in Advanced Colorectal Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(17):1757-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/18946061/pubmed\" id=\"18946061\" target=\"_blank\">",
"        18946061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maubec E, Petrow P, Scheer-Senyarich I, et al, &ldquo;Phase II Study of Cetuximab as First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(25):3419-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/21810686/pubmed\" id=\"21810686\" target=\"_blank\">",
"        21810686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Colon Cancer,&rdquo; Version 3.2012. Available at file://www.nccn.org/professionals/physician_gls/PDF/colon.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Neil BH, Allen R, Spigel DR, et al, &ldquo;High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(24):3644-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/17704414/pubmed\" id=\"17704414\" target=\"_blank\">",
"        17704414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeiffer P, Bjerregarrd JK, Qvortrup C, et al, &ldquo;Simplification of Cetuximab (Cet) Administration: Double Dose Every Second Week as a 60 Minute Infusion,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(18S):4133 [abstract 4133 from 2007 ASCO Annual Meeting Proceedings, Part I].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeiffer P, Nielsen D, Bjerregaard J, et al, &ldquo;Biweekly Cetuximab and Irinotecan as Third-Line Therapy in Patients With Advanced Colorectal Cancer After Failure to Irinotecan, Oxaliplatin and 5-Fluorouracil,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(6):1141-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/18281264/pubmed\" id=\"18281264\" target=\"_blank\">",
"        18281264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pirker R, Pereira JR, Szczesna A, et al, &ldquo;Cetuximab Plus Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9674):1525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/19410716/pubmed\" id=\"19410716\" target=\"_blank\">",
"        19410716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pirker R, Pereira JR, von Pawel J, et al, &ldquo;EGFR Expression as a Predictor of Survival for First-Line Chemotherapy Plus Cetuximab in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Data From the Phase 3 FLEX Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(1):33-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/22056021/pubmed\" id=\"22056021\" target=\"_blank\">",
"        22056021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tra F, Fesen MR, Pianalto M, et al, &ldquo;Albuterol-Based Premedication Therapy for the Prevention of Cetuximab Infusion-Related Reactions,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):17040 [abstract 17040 from ASCO 2008  Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, K&ouml;hne CH, L&aacute;ng I, et al, &ldquo;Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor",
"      <i>",
"       KRAS",
"      </i>",
"      and",
"      <i>",
"       BRAF",
"      </i>",
"      Mutation Status,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(15):2011-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/21502544/pubmed\" id=\"21502544\" target=\"_blank\">",
"        21502544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Lang, I, D&rsquo;haens G, et al, &ldquo;",
"      <i>",
"       KRAS",
"      </i>",
"      Status and Efficacy in the First-Line Treatment of Patients With Metastatic Colorectal Cancer (mCRC) Treated With FOLFIRI With or Without Cetuximab: The CRYSTAL Experience,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):2 [abstract 2 from ASCO 2008 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Mesia R, Rivera F, et al, \"Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(11):1116-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?9/58/10151/abstract-text/18784101/pubmed\" id=\"18784101\" target=\"_blank\">",
"        18784101",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9209 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10151=[""].join("\n");
var outline_f9_58_10151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708650\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149013\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1995494\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149033\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149015\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149016\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682571\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682572\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149034\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148996\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148983\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148998\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148997\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6825474\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110716\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149031\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149001\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148986\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299006\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148990\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148992\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149004\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149023\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149005\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370503\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148994\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149006\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148985\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149000\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/62/30692?source=related_link\">",
"      Cetuximab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_58_10152="Pemphigus vulgaris DIF";
var content_f9_58_10152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris direct immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intercellular pattern of IgG antibody binding is evident on direct immunofluorescence in this specimen from a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10152=[""].join("\n");
var outline_f9_58_10152=null;
var title_f9_58_10153="Anisakiasis life cycle";
var content_f9_58_10153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Anisakiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adult stages of",
"    <em>",
"     Anisakis simplex",
"    </em>",
"    or",
"    <em>",
"     Pseudoterranova decipiens",
"    </em>",
"    reside in the stomach of marine mammals, where they are embedded in the mucosa, in clusters. Unembryonated eggs produced by adult females are passed in the feces of marine mammals",
"    <strong>",
"     (1)",
"    </strong>",
"    . The eggs become embryonated in water, and first-stage larvae are formed in the eggs. The larvae molt, becoming second-stage larvae",
"    <strong>",
"     (2a)",
"    </strong>",
"    , and after the larvae hatch from the eggs, they become free-swimming",
"    <strong>",
"     (2b)",
"    </strong>",
"    . Larvae released from the eggs are ingested by crustaceans",
"    <strong>",
"     (3)",
"    </strong>",
"    . The ingested larvae develop into third-stage larvae that are infective to fish and squid",
"    <strong>",
"     (4)",
"    </strong>",
"    . The larvae migrate from the intestine to the tissues in the peritoneal cavity and grow up to 3 cm in length. Upon the host's death, larvae migrate to the muscle tissues, and through predation, the larvae are transferred from fish to fish. Fish and squid maintain third-stage larvae that are infective to humans and marine mammals",
"    <strong>",
"     (5)",
"    </strong>",
"    . When fish or squid containing third-stage larvae are ingested by marine mammals, the larvae molt twice and develop into adult worms. The adult females produce eggs that are shed by marine mammals",
"    <strong>",
"     (6)",
"    </strong>",
"    . Humans become infected by eating raw or undercooked infected marine fish",
"    <strong>",
"     (7)",
"    </strong>",
"    . After ingestion, the anisakid larvae penetrate the gastric and intestinal mucosa, causing the symptoms of anisakiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Anisakiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Anisakiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Anisakiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10153=[""].join("\n");
var outline_f9_58_10153=null;
var title_f9_58_10154="Recognition of monoclonal proteins";
var content_f9_58_10154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recognition of monoclonal proteins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?9/58/10154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?9/58/10154/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?9/58/10154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?9/58/10154/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?9/58/10154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?9/58/10154/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?9/58/10154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoclonal gammopathies (paraproteinemias or dysproteinemias) are a group of disorders characterized by the proliferation of a single clone of plasma cells, which produces an immunologically homogeneous protein commonly referred to as a paraprotein or monoclonal protein (M-protein, where the \"M\" stands for monoclonal). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition of an M-protein'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A complete immunoglobulin consists of two heavy polypeptide chains of the same class designated by a capital letter and a corresponding Greek letter:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gamma in IgG",
"     </li>",
"     <li>",
"      Alpha in IgA",
"     </li>",
"     <li>",
"      Mu in IgM",
"     </li>",
"     <li>",
"      Delta in IgD",
"     </li>",
"     <li>",
"      Epsilon in IgE",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The heavy polypeptide chains are further subdivided: IgG has four subclasses (IgG1, IgG2, IgG3, and IgG4) and IgA has two (IgA1 and IgA2). To form the intact immunoglobulin, the paired heavy chains are associated with two light chains of the same type, either kappa or lambda, but not both (",
"    <a class=\"graphic graphic_figure graphicRef56393 \" href=\"mobipreview.htm?1/2/1071\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=see_link\">",
"     \"Structure of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of serum or urine to detect the presence of an M-protein and identify it according to its heavy chain class and light chain type requires a sensitive, rapid, and dependable method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic will review the methodologies available for these purposes. Discussions of monoclonal gammopathies and the diagnosis of multiple myeloma and Waldenstr&ouml;m macroglobulinemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF AN M-PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;An M-protein (paraprotein, monoclonal protein, M-component) is a monoclonal immunoglobulin secreted by an abnormally expanded clone of plasma cells in an amount that can be detected by immunofixation of serum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urine, or (rarely) other body fluids (eg, jejunal fluid in alpha heavy chain disease), or by the serum free light chain assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The M-protein can be an intact immunoglobulin (ie, containing both heavy and light chains), can be composed of only light chains (ie, light chain myeloma, light chain deposition disease, AL (light chain) amyloidosis), or rarely can consist of heavy chains only (ie, heavy chain disease, heavy chain deposition disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12470?source=see_link\">",
"     \"The heavy chain diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL RELEVANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clonal size",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an M-protein in the serum or urine indicates an underlying clonal plasma cell or lymphoproliferative disorder (",
"    <a class=\"graphic graphic_table graphicRef70820 \" href=\"mobipreview.htm?43/21/44380\">",
"     table 1",
"    </a>",
"    ). In some cases, the clonal process producing the M-protein is malignant and is associated with evidence of neoplastic disease infiltrating bone, lymph nodes, liver, spleen, or other organs (eg, multiple myeloma, solitary plasmacytoma, Waldenstr&ouml;m macroglobulinemia). In other cases, the M-protein is produced by a small limited premalignant clonal expansion, and causes no symptoms (eg, monoclonal gammopathy of undetermined significance, MGUS). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, premalignant disorders in medicine have limited clinical consequences until malignant transformation occurs. However, in the case of plasma cell disorders since the clonal cells secrete immunoglobulin antibodies, disabling or fatal disease can occur even when the clonal expansion is premalignant due to one or more potential adverse properties of the secreted M-protein, such as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ability to agglutinate red cells (eg, cold agglutinin disease) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=see_link\">",
"       \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Insolubility at low temperatures (eg, cryoglobulinemia) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased viscosity (eg, Waldenstr&ouml;m macroglobulinemia) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deposition in tissues with resulting organ dysfunction (eg, AL (light chain) amyloidosis or the immunoglobulin deposition diseases) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"       \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Neuropathy (paraneoplastic neuropathy; eg, MGUS, Waldenstr&ouml;m macroglobulinemia, AL amyloidosis, POEMS syndrome) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=see_link\">",
"       \"POEMS syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"       \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, M-proteins may be part of an asymptomatic limited clonal expansion of plasma cells (eg, MGUS), be a manifestation of a malignancy (eg, myeloma, macroglobulinemia), or may lead to life-threatening complications even if the clonal expansion that produced the M-protein is limited (eg, primary amyloidosis). The clinician seeing a patient with an M-protein must therefore make the appropriate diagnosis (",
"    <a class=\"graphic graphic_table graphicRef70820 \" href=\"mobipreview.htm?43/21/44380\">",
"     table 1",
"    </a>",
"    ) and initiate effective therapy in a timely manner, in order to prevent irreversible organ damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shortening of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interference with laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a circulating M-protein may interfere with one or more laboratory tests performed on liquid-based automated analyzers, either by precipitating during the analysis, or by virtue of its specific binding properties.",
"   </p>",
"   <p>",
"    The most common artifacts are a low value for HDL cholesterol, a high value for bilirubin, as well as altered measurement of inorganic phosphate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Other examples include interference with measurement of LDL cholesterol, C-reactive protein, antistreptolysin-O, creatinine, glucose, sodium, chloride, bicarbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/9\">",
"     9",
"    </a>",
"    ], urea nitrogen, albumin, iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/10\">",
"     10",
"    </a>",
"    ], and inorganic calcium (",
"    <a class=\"graphic graphic_table graphicRef83087 \" href=\"mobipreview.htm?30/7/30844\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Re-analysis using a different method or sample dilution can be employed for obtaining accurate measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/4\">",
"     4",
"    </a>",
"    ]. These events may occur in patients whose clinicians are unaware of the presence of an underlying M-protein and might result in the mismanagement of patients with monoclonal gammopathy, especially as regards measurement of HDL and LDL cholesterol and estimation of cardiovascular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANALYSIS OF SERUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of serum for the presence of M-proteins, or for the evaluation of a patient with increased total serum proteins, is classically performed using electrophoretic techniques, supplemented with additional tests for protein quantification and methodologies to determine whether the protein arises from a single clone (ie, monoclonal) (",
"    <a class=\"graphic graphic_table graphicRef70590 \" href=\"mobipreview.htm?27/29/28124\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serum protein electrophoresis (SPEP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum protein electrophoresis (SPEP) is an inexpensive and easy to perform screening procedure to detect an M-protein. SPEP is usually done by the agarose gel method (agarose gel electrophoresis). The resulting M-protein, if found, can be quantitated using a densitometer tracing of the gel (",
"    <a class=\"graphic graphic_figure graphicRef67685 graphicRef74787 \" href=\"mobipreview.htm?14/5/14420\">",
"     figure 2A-B",
"    </a>",
"    ). Thus the SPEP serves two purposes: detect presence or absence of an M-protein in the serum, and, in conjunction with the total protein concentration, enable measurement of the concentration (&ldquo;size&rdquo;) of the M-protein.",
"   </p>",
"   <p>",
"    Capillary zone electrophoresis is an alternative and slightly more sensitive method of performing SPEP. It measures protein on-line via light absorbance techniques; protein stains are not necessary and no point of application is seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The electrophoretograms are similar to those produced with high resolution agarose gel SPEP.",
"   </p>",
"   <p>",
"    In the electrophoretic methodologies (agarose or capillary zone), proteins are classified by their final position after electrophoresis is complete into five general regions: albumin, alpha-1, alpha-2, beta, and gamma (",
"    <a class=\"graphic graphic_figure graphicRef67685 \" href=\"mobipreview.htm?21/3/21566\">",
"     figure 2A",
"    </a>",
"    ). These regions, which also use a Greek lettering system, do",
"    <strong>",
"     not",
"    </strong>",
"    refer to the immunoglobulin class to which an M-protein may belong, and refer only to mobility through the support medium. The various immunoglobulin classes (IgG, IgA, IgM, IgD, and IgE) are usually located in the gamma region of the SPEP, but they may also be found in the beta-gamma and beta regions, and may occasionally extend into the alpha-2 globulin area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;SPEP is indicated in all patients in whom multiple myeloma, Waldenstr&ouml;m macroglobulinemia, primary amyloidosis, or a related disorder is suspected. The initial SPEP should always be performed in combination with serum immunofixation in order to determine and confirm monoclonality, and to determine the immunoglobulin heavy and light chain class if an M-protein is identified. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serum immunofixation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SPEP should also be considered in any patient with an elevated total serum protein or otherwise unexplained signs and symptoms suggestive of the presence of a plasma cell disorder. These include any one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained anemia, back pain, weakness, or fatigue",
"     </li>",
"     <li>",
"      Osteopenia, osteolytic lesions, or spontaneous fractures",
"     </li>",
"     <li>",
"      Renal insufficiency with a bland urine sediment",
"     </li>",
"     <li>",
"      Heavy proteinuria in a patient over age 40",
"     </li>",
"     <li>",
"      Hypercalcemia",
"     </li>",
"     <li>",
"      Hypergammaglobulinemia",
"     </li>",
"     <li>",
"      Immunoglobulin deficiency",
"     </li>",
"     <li>",
"      Bence Jones proteinuria",
"     </li>",
"     <li>",
"      Unexplained peripheral neuropathy",
"     </li>",
"     <li>",
"      Recurrent infections",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate or serum viscosity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, the presence of a localized band or spike on SPEP in adults with nephrotic syndrome, refractory heart failure, orthostatic hypotension, peripheral neuropathy, carpal tunnel syndrome, or malabsorption strongly suggests the possibility of primary amyloidosis (AL), and requires confirmation with immunofixation studies. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serum immunofixation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Monoclonal gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A monoclonal protein (M-protein) usually presents as a single narrow peak, like a church spire, in the gamma, beta, or alpha-2 region of the densitometer tracing or as a dense, discrete band on the agarose gel (",
"    <a class=\"graphic graphic_figure graphicRef67685 graphicRef74787 \" href=\"mobipreview.htm?14/5/14420\">",
"     figure 2A-B",
"    </a>",
"    ). In approximately 5 percent of sera with an M-protein, two M-proteins are present (biclonal gammopathy) (",
"    <a class=\"graphic graphic_figure graphicRef54186 graphicRef74787 \" href=\"mobipreview.htm?34/15/35061\">",
"     figure 2B-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/14\">",
"     14",
"    </a>",
"    ]. Serum immunofixation must be performed in order to determine clonality (eg, monoclonal, biclonal, polyclonal). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serum immunofixation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A monoclonal protein can be present in a number of different disorders (monoclonal gammopathies), including B-cell and plasma cell proliferations. The most common of these are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef70820 \" href=\"mobipreview.htm?43/21/44380\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1965968\">",
"    <span class=\"h3\">",
"     Biclonal gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally a patient may have two different monoclonal proteins, and this is referred to as biclonal gammopathy (",
"    <a class=\"graphic graphic_figure graphicRef66994 \" href=\"mobipreview.htm?11/23/11638\">",
"     figure 3",
"    </a>",
"    ). Biclonal gammopathies are typically detected when two different heavy or light chain classes of M-proteins are detected on immunofixation (eg, an IgA kappa M-protein and an IgM lambda M-protein in the same patient). Sometimes, the presence of monomers and polymers of an M-protein may produce two spikes on the SPEP and can resemble a biclonal gammopathy. Patients with biclonal gammopathy can have a malignancy such as myeloma, or may just have a premalignancy. Patients with biclonal gammopathy of undetermined significance have the same clinical spectrum as those with monoclonal gammopathy of undetermined significance (MGUS), and should be followed in the same manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4041?source=see_link\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Polyclonal gammopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a broad-based peak or band, usually of gamma mobility, suggests a",
"    <strong>",
"     polyclonal",
"    </strong>",
"    increase in immunoglobulins, most often due to an infectious, inflammatory, or reactive process (",
"    <a class=\"graphic graphic_figure graphicRef74708 graphicRef74787 \" href=\"mobipreview.htm?11/46/12004\">",
"     figure 2B, 2D",
"    </a>",
"    ). In chronic hepatitis, for example, the gamma component may reach 6 or 7",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Polyclonal gammopathy may on occasion be present without evidence of an underlying process.",
"   </p>",
"   <p>",
"    In a retrospective cohort study of 148 patients seen at the Mayo Clinic, in whom a polyclonal gamma globulin level &ge;3.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    was found, a single associated medical disorder was present in 130. No patient developed myeloma or a clonal plasma cell proliferative disorder. The most common disorders were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver disease &mdash; 61 percent",
"     </li>",
"     <li>",
"      Connective tissue disease &mdash; 22 percent",
"     </li>",
"     <li>",
"      Chronic infection &mdash; 6 percent",
"     </li>",
"     <li>",
"      Hematologic disorders &mdash; 5 percent",
"     </li>",
"     <li>",
"      Non-hematologic malignancy &mdash; 3 percent",
"     </li>",
"     <li>",
"      Other &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polyclonal gammopathy, along with bone marrow plasmacytosis, is a common finding in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these patients also have an increased incidence of clonal plasma cell disorders (eg, MGUS, multiple myeloma, plasmablastic lymphoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=see_link&amp;anchor=H1560506326#H1560506326\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Plasma cell disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypogammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogammaglobulinemia (&lt;0.6",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is characterized by a decrease in size of the gamma mobility component on SPEP, and should be documented by quantitation of serum IgG, IgA, and IgM levels. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Quantitation of immunoglobulins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypogammaglobulinemia may be congenital, sex-linked,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    part of a combined immunodeficiency state. It may also be acquired, as in multiple myeloma, primary amyloidosis, chronic lymphocytic leukemia, lymphoma, or the nephrotic syndrome (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Panhypogammaglobulinemia occurs in about 10 percent of patients with multiple myeloma. Most of these patients have a Bence Jones protein (monoclonal free kappa or lambda light chains) in the urine, but lack intact immunoglobulins in the serum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Panhypogammaglobulinemia is seen in approximately 20 percent of patients with primary amyloidosis, often associated with a nephrotic pattern (mainly albumin with nonselective globulin loss) in the urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2213735\">",
"    <span class=\"h3\">",
"     Other SPEP patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other patterns may be observed on the SPEP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in serum albumin and an increase in alpha-1 and alpha-2 globulins may be present in patients with infection or metastatic malignancy.",
"     </li>",
"     <li>",
"      Marked reduction of the alpha-1 globulin component is usually due to a deficiency of alpha-1 antitrypsin.",
"     </li>",
"     <li>",
"      Two albumin bands (bisalbuminemia) are rarely found. This familial abnormality produces no symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     False negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small M-protein may be present even when quantitative immunoglobulin values, beta and gamma mobility components on SPEP, and total serum protein concentrations are all within normal limits. If a clonal plasma cell disorder is suspected, the most sensitive tests to screen for presence of a monoclonal protein are serum and urine immunofixation, and the serum free light chain assay. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serum immunofixation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2212928\">",
"     'Serum free light chains'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following caveats need to be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In alpha heavy chain disease (HCD), which occurs in patients with a form of small intestinal lymphoma called immunoproliferative small intestinal disease (IPSID), one never sees a localized band or sharp peak, presumably because of the tendency of these chains to polymerize, or due to their high carbohydrate content [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. In some patients these proteins can be found in jejunal fluid but not in the serum. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12470?source=see_link&amp;anchor=H9#H9\">",
"       \"The heavy chain diseases\", section on 'Alpha HCD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In mu HCD, panhypogammaglobulinemia is a prominent feature and a localized band is found in only 40 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12470?source=see_link&amp;anchor=H11#H11\">",
"       \"The heavy chain diseases\", section on 'Mu HCD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an occasional patient with gamma HCD, the electrophoretic tracing may appear broad and heterogeneous rather than showing a localized band [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/24,27,28\">",
"       24,27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12470?source=see_link&amp;anchor=H10#H10\">",
"       \"The heavy chain diseases\", section on 'Gamma HCD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An M-protein may produce a broad band in the agarose gel, suggesting a polyclonal pattern. This can occur when an M-protein complexes with other plasma components, or when there are IgM dimers and pentamers, IgA polymers, or IgG aggregates.",
"     </li>",
"     <li>",
"      Some patients make only monoclonal light chains (Bence Jones proteinemia), which are usually present in concentrations too low to be visible as a spike in the agarose gel, because of rapid excretion in the urine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/29\">",
"       29",
"      </a>",
"      ]. The serum concentrations will rise if such patients develop renal failure.",
"     </li>",
"     <li>",
"      In some patients with IgD or IgE myeloma, the M-protein spike may be small and easily overlooked.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     False positive results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum protein elements other than immunoglobulins may falsely suggest the presence of an M-protein. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrinogen (in plasma) is seen as a discrete band between the beta and gamma mobility regions. This is indistinguishable from an M-protein; addition of thrombin to the specimen will produce a clot if fibrinogen is present. The presence of fibrinogen is established if the discrete band is no longer detected when electrophoresis is repeated after the addition of thrombin.",
"     </li>",
"     <li>",
"      Hemoglobin-haptoglobin complexes secondary to hemolysis may appear as a large band in the alpha-2-globulin region.",
"     </li>",
"     <li>",
"      High concentrations of transferrin in patients with iron-deficiency anemia may produce a localized band in the beta region.",
"     </li>",
"     <li>",
"      Nephrotic syndrome is often associated with increased alpha-2 and beta bands which can be mistaken for an M-protein. Serum albumin and gamma globulin concentrations are usually reduced in this setting.",
"     </li>",
"     <li>",
"      Nonspecific increases in acute phase reactants or certain hyperlipoproteinemias may result in increases in alpha-1 bands.",
"     </li>",
"     <li>",
"      A common artifact is the presence of a protein band at the point of application of the sample. A clue to the presence of this artifact is the presence of this band on simultaneously performed samples from multiple patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serum immunofixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;SPEP is a useful initial procedure to screen for an M-protein, but has two drawbacks. First, it is not as sensitive when M-proteins are small. An M-protein may be easily overlooked or an apparent M-protein may actually represent a polyclonal increase in immunoglobulins or another protein. Second, if an M-protein is present, the immunoglobulin heavy and light chain class cannot be determined from the SPEP. Consequently, the laboratory must perform serum immunofixation in order to ascertain the presence of an M-protein and to determine its type. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum immunofixation is critical for the differentiation of a monoclonal from a polyclonal increase in immunoglobulins. In traditional immunofixation, the patient's serum is electrophoresed into at least five separate lanes. Following electrophoretic separation of the serum proteins, each sample is overlaid with a different monospecific antibody, usually three for the heavy chain component and two for the light chain component (eg, anti-gamma, anti-mu, anti-alpha, anti-kappa, and anti-lambda, respectively). Precipitation of proteins (ie, the antigen-antibody complex) is allowed to occur, followed by washing (nonprecipitated proteins wash out) and staining of the remaining immunoprecipitates.",
"   </p>",
"   <p>",
"    Immunosubtraction is an alternative procedure to serum immunofixation. In this procedure the serum sample is incubated with Sepharose beads coupled with anti-gamma, -alpha, -mu, -kappa, and -lambda antisera. After incubation with each of the heavy and light chain antisera, the supernatants are reanalyzed to determine which reagent(s) removed the electrophoretic abnormality. The immunosubtraction procedure is technically less demanding, is automated, and is therefore a useful alternative to serum immunofixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. It has the same indications, and accomplishes the same goals, as serum immunofixation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An M-protein is characterized on immunofixation by the combined presence of a sharp, well-defined band associated with a single heavy-chain class and a sharp, well-defined band with similar mobility characteristics that reacts with either kappa or lambda light chain antisera, but not both (",
"    <a class=\"graphic graphic_figure graphicRef55916 \" href=\"mobipreview.htm?4/39/4735\">",
"     figure 4",
"    </a>",
"    ). In comparison, an M-protein is characterized on immunosubtraction by the elimination of the electrophoretic abnormality by incubating with a single heavy-chain class and with either anti-kappa or anti-lambda, but not both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum immunofixation is more sensitive than SPEP, and also determines the heavy and light chain type of the monoclonal protein. However, unlike SPEP, immunofixation does not give an estimate of the size of the M-protein (ie, its serum concentration), and thus should be done in conjunction with electrophoresis. Serum immunofixation should be performed when a",
"    <strong>",
"     sharp",
"    </strong>",
"    band or peak is found in the agarose gel (ie, a monoclonal protein on SPEP) or when multiple myeloma, macroglobulinemia, primary amyloidosis, solitary or extramedullary plasmacytoma, or a related disorder is suspected, despite a normal SPEP pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunofixation will detect a serum M-protein at a concentration of at least 0.02",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and a urine M-protein at a concentration of &ge;0.004",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/13\">",
"     13",
"    </a>",
"    ]. It should always be performed in the presence of otherwise unexplained sensory motor peripheral neuropathy, nephrotic syndrome, refractory heart failure, orthostatic hypotension, carpal tunnel syndrome, malabsorption, or whenever the clinical situation suggests the possibility of primary amyloidosis (AL). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also a variety of other indications for immunofixation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of a small M-protein in the presence of normal or increased background immunoglobulins.",
"     </li>",
"     <li>",
"      In patients with multiple myeloma or macroglobulinemia in whom treatment has resulted in disappearance of the band on SPEP.",
"     </li>",
"     <li>",
"      Recognition and distinction of biclonal (two M-proteins) (",
"      <a class=\"graphic graphic_figure graphicRef66994 \" href=\"mobipreview.htm?11/23/11638\">",
"       figure 3",
"      </a>",
"      ) or triclonal (three M-proteins) (",
"      <a class=\"graphic graphic_figure graphicRef69270 \" href=\"mobipreview.htm?24/41/25238\">",
"       figure 5",
"      </a>",
"      ) gammopathies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/30\">",
"       30",
"      </a>",
"      ]. Such multiple M-proteins may have only a single band or spike on SPEP, and may otherwise be missed. (See",
"      <a class=\"local\" href=\"#H1965968\">",
"       'Biclonal gammopathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the possibility of IgD and IgE monoclonal proteins must be excluded by immunofixation using IgD and IgE antisera in all patients with a monoclonal light chain in the serum but no reactivity to anti-G, anti-M, or anti-A.",
"   </p>",
"   <p>",
"    When following patients with multiple myeloma, MGUS, or a related disorder, once the presence of a monoclonal protein and its type are initially confirmed by immunofixation, it is not necessary to repeat immunofixation unless needed to document complete response to therapy. Patients can usually be followed with electrophoresis of serum (SPEP) or urine (UPEP) proteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2212928\">",
"    <span class=\"h2\">",
"     Serum free light chains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum free light chain (FLC) assay is a sensitive antibody-based system that can detect low concentrations of monoclonal free light chains (ie, kappa or lambda) in the serum. This assay is of particular use in the approximately 16 percent of patients with multiple myeloma that produce only a Bence Jones protein (free light chain that is not bound to a heavy chain), often in concentrations too low to be detected by routine serum immunofixation techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/20\">",
"     20",
"    </a>",
"    ]. Under such circumstances, or when primary systemic amyloidosis or light-chain-deposition disease are suspected, it is routine to analyze a 24-hour urine collection for the presence of free light chains. The serum FLC assay complements and potentially obviates the need for a 24-hour UPEP when screening for myeloma and related plasma cell disorders. (See",
"    <a class=\"local\" href=\"#H2212935\">",
"     'Indications and uses'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31\">",
"     '24-hour urine protein electrophoresis (UPEP)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The serum FLC assay can detect low concentrations of monoclonal free light chains in serum. Using this assay, normal levels were as follows (95 percent confidence intervals) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Free serum kappa light chains &mdash; 3.3 to 19.4",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"     <li>",
"      Free serum lambda light chains &mdash; 5.7 to 26.3",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"     <li>",
"      Ratio of kappa to lambda free light chains &mdash; 0.26 to 1.65",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This FLC assay is more sensitive for the detection of monoclonal free light chains than urine immunofixation. This was illustrated in a study of paired serum and urine samples from patients with multiple myeloma who tested positive for either kappa or lambda monoclonal free light chains in their serum; only 51 and 35 percent, respectively, of their paired urine samples were positive for Bence Jones protein on urine immunofixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When this assay was applied to sera from patients previously diagnosed as having nonsecretory myeloma, the improved sensitivity allowed 19 of 28 to be reclassified as secretory light chain myeloma (",
"    <a class=\"graphic graphic_figure graphicRef56523 \" href=\"mobipreview.htm?1/57/1951\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Non-secretory myeloma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2212935\">",
"    <span class=\"h3\">",
"     Indications and uses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of serum FLCs is useful in a number of settings, such as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis and monitoring progress of patients with non-secretory myeloma and oligosecretory (&lt;1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      monoclonal protein in the serum and &lt;200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      monoclonal protein in the urine) myeloma.",
"     </li>",
"     <li>",
"      Diagnosis and monitoring progress of patients with light chain myeloma as well as primary systemic amyloidosis, in whom the underlying clonal plasma cell disorder may otherwise be difficult to detect and monitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Predicting risk of progression of MGUS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4041?source=see_link&amp;anchor=H22391048#H22391048\">",
"       \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Predicting risk of progression of smoldering multiple myeloma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=see_link&amp;anchor=H30#H30\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Smoldering multiple myeloma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Predicting risk of progression of solitary plasmacytoma of bone. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44535?source=see_link&amp;anchor=H15#H15\">",
"       \"Diagnosis and management of solitary plasmacytoma of bone\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diagnosis, monitoring during and after treatment, and perhaps predicting prognosis of patients with multiple myeloma and an intact immunoglobulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Potentially obviating the initial need for urine protein studies in the initial evaluation for monoclonal gammopathies when serum FLC analysis is performed along with serum protein electrophoresis and serum immunoelectrophoresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/40\">",
"       40",
"      </a>",
"      ]. If a monoclonal protein is found, electrophoresis and immunofixation of an aliquot from a 24-hour urine collection should then be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=see_link&amp;anchor=H90175591#H90175591\">",
"       \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2212942\">",
"    <span class=\"h3\">",
"     Use in patients with renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normally rapid renal clearance of serum FLCs is reduced in the presence of renal insufficiency (eg, creatinine clearance &lt;60",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    As a result, serum FLC concentrations rise as the glomerular filtration rate falls, and may be 20 to 30 times normal in end-stage renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating the",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    ratio in patients with renal insufficiency have had conflicting results. While some studies have suggested that the ratio is elevated in patients with severely reduced renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/42\">",
"     42",
"    </a>",
"    ], others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/31,43,44\">",
"     31,43,44",
"    </a>",
"    ]. As an example, one study demonstrated that the",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    ratio, which is normally in the range of 0.26 to 1.65, may rise to as high as 3.1 in the presence of dialysis dependent renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/42\">",
"     42",
"    </a>",
"    ]. The change in",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    ratios with increasing renal impairment is of potential clinical relevance in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients might be misclassified as having a kappa monoclonal gammopathy because of an increased",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      ratio due solely to renal insufficiency.",
"     </li>",
"     <li>",
"      Patients with a lambda monoclonal gammopathy along with renal insufficiency might have a relatively normal",
"      <span class=\"nowrap\">",
"       kappa/lambda",
"      </span>",
"      ratio and be missed because of the relative increase in kappa chains due to the renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Kappa/lambda",
"    </span>",
"    ratios &gt;3.0 are unlikely to be due to renal insufficiency alone. It is difficult to interpret",
"    <span class=\"nowrap\">",
"     kappa/lambda",
"    </span>",
"    ratios between 1.65 and 3.0 in the context of renal insufficiency. In such cases, further investigation with a 24-hour urine protein electrophoresis and urine immunofixation helps to guide interpretation. If both of these subsequent studies are normal and the patient has no other symptoms suggestive of a plasma cell dyscrasia, then the increased ratio is likely due to the renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2213249\">",
"    <span class=\"h2\">",
"     Serum viscosity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum viscosity should be performed in any patient with a monoclonal gammopathy and signs and symptoms suggesting the hyperviscosity syndrome. These symptoms include: oronasal bleeding, blurred vision, dilatation of retinal veins, flame-shaped retinal hemorrhages, unexplained heart failure, or neurologic symptoms such as headaches, vertigo, nystagmus, deafness, ataxia, diplopia, paresthesias, stupor, or somnolence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Waldenstr&ouml;m macroglobulinemia, with increased concentrations of IgM, is the most common cause of hyperviscosity, but hyperviscosity can also occur in patients with high concentrations of monoclonal IgA or IgG. Serum viscosity should be determined whenever the monoclonal IgM protein spike is &gt;4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or the IgA or IgG protein spike is &gt;6",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The normal value for serum viscosity is 1.5 centipoise (CP), but hyperviscosity symptoms are rarely present unless the viscosity is &gt;4 CP. However, many laboratories report viscosity in relative terms (eg, relative to distilled water or saline). The normal relative viscosity in our laboratory is 1.8. Because of the often poor correlation between viscosity and symptoms, and the fact that relative and absolute (in centipoise, see below) viscosities of plasma are similar, these two units can be used interchangeably.",
"   </p>",
"   <p>",
"    The relationship between serum viscosity and IgM protein concentration is nonlinear. Thus, with low serum IgM concentrations, an increase of 1 to 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    produces only a small increase in serum viscosity, but with IgM levels of 4 to 5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    an increment of 1 to 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    greatly increases viscosity. In addition, the relationship between serum viscosity and symptoms of hyperviscosity is not precise. Although many patients have symptoms when the viscosity is &gt;4 centipoise (CP), most have symptoms when the viscosity reaches 6 to 7 CP. However, we have also seen higher viscosities in the absence of symptoms or physical findings of the hyperviscosity syndrome.",
"   </p>",
"   <p>",
"    The specific viscosity level at which clinical symptoms occur is affected not only by the serum protein concentration but also by molecular characteristics of the protein, aggregation of protein molecules, and the simultaneous presence of diseases involving the microvasculature, hematocrit, and cardiac status. Consequently, clinical evaluation of the patient is important. The decision to perform plasmapheresis should be made on the basis of signs and symptoms of hyperviscosity rather than the viscosity value per se. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Hyperviscosity syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37626?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia\", section on 'Emergent management of hyperviscosity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is useful to measure the serum viscosity and to perform SPEP before and after each plasmapheresis to determine effectiveness. Such patients should also be monitored by periodic SPEP. If the serum M-protein values increase or if symptoms or signs of hyperviscosity recur, the serum viscosity should be repeated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Quantitation of immunoglobulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitation of immunoglobulins is the most useful technique for the detection of hypogammaglobulinemia. The use of a rate nephelometer is a good method for this purpose. The degree of turbidity produced by antigen-antibody interaction is measured by nephelometry in the near ultraviolet regions. Because the method is not affected by the molecular size of the antigen, the nephelometric technique accurately measures 7S IgM, polymers of IgA, or aggregates of IgG.",
"   </p>",
"   <p>",
"    Estimation of quantitative immunoglobulins by nephelometry does not allow an assessment of monoclonality. Increased levels can be due to polyclonal or monoclonal elevations; clonality needs to be established using immunofixation. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Serum immunofixation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the reason is not well understood, nephelometric levels of IgM are often 1000 to 2000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    greater than expected on the basis of the SPEP densitometry tracing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/46\">",
"     46",
"    </a>",
"    ]. Because of the overestimation of IgM by nephelometry, it has been recommended that SPEP followed by densitometry is preferable, the results of which usually more closely agree with the clinical presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/47\">",
"     47",
"    </a>",
"    ]. IgG and IgA may also be spuriously increased using nephelometry.",
"   </p>",
"   <p>",
"    Quantitation of immunoglobulins using nephelometry is a useful adjunct to the SPEP and UPEP in following patients with multiple myeloma specifically to assess response to therapy. However, when assessing response, SPEP values should only be compared with SPEP values, and quantitative immunoglobulin values only with quantitative immunoglobulin values.",
"   </p>",
"   <p>",
"    In certain situations quantitative immunoglobulin values may be more reliable than the SPEP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small beta-migrating M-proteins (usually IgA M-proteins) are contaminated by normal immunoglobulins that may be greater in quantity than the M-spike itself.",
"     </li>",
"     <li>",
"      When the M-spike is so large (&gt;4",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      and narrow on agarose that the SPEP underestimates the actual immunoglobulin level (by more than 1.5",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      due to technical staining properties of the agarose gel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ANALYSIS OF URINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an M-protein in the urine is estimated by urine protein electrophoresis (UPEP) and urine protein immunofixation. Quantitation of the urine M-protein also requires a simultaneous measurement of 24-hour total urine protein. Although dipsticks are used in many laboratories to screen for the presence of protein in the urine, these tests are often unable to detect Bence Jones protein (free kappa or lambda light chains). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link&amp;anchor=H7#H7\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Standard urine dipstick'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     24-hour urine protein electrophoresis (UPEP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine protein electrophoresis (UPEP) is analogous to the serum protein electrophoresis (SPEP), and is used to detect M-proteins in the urine by an electrophoretic method. Once detected, the monoclonality must be confirmed using urine immunofixation. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Urine immunofixation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A 24-hour urine collection is necessary for determination of the total amount of protein excreted in the urine per day. The quantity of M-protein excreted is determined by measuring the size (percent) of the M-spike in the densitometer tracing and multiplying it by the total 24-hour urinary protein excretion. The amount of protein can be expressed as",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    but it is much more useful to report the M-protein in",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours because of wide variability in the daily urinary volume. The 24-hour urine specimen requires no preservative and may be kept at room temperature during collection.",
"   </p>",
"   <p>",
"    On UPEP, a urinary M-protein is seen as a dense localized band on agarose or a tall narrow peak on the densitometer tracing (",
"    <a class=\"graphic graphic_figure graphicRef55073 \" href=\"mobipreview.htm?7/20/7503\">",
"     figure 7",
"    </a>",
"    ). Generally, the amount of urinary monoclonal protein correlates directly with the size of the plasma cell burden, as long as renal function is relatively normal. Consequently, urinary M-protein excretion is useful in determining the response to therapy or progression of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with a diagnosis of a plasma cell dyscrasia should have a baseline UPEP (and immunofixation) of an aliquot from a 24-hour urine collection. This test is essential to detect the presence of potentially nephrotoxic concentrations of urinary light chains. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    UPEP testing is subsequently required to detect progression and to monitor response to therapy in patients who have urinary monoclonal proteins at baseline.",
"   </p>",
"   <p>",
"    UPEP (and immunofixation) has been used also as a standard screening test for patients in whom there is clinical suspicion for a monoclonal plasma cell proliferative disorder such as myeloma or primary amyloidosis. The serum free light chain assay can be used as an alternative method. (See",
"    <a class=\"local\" href=\"#H2212928\">",
"     'Serum free light chains'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Urine immunofixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine immunofixation is the preferred method for identification of a monoclonal protein in the urine. As in the case of serum immunofixation it is more sensitive than UPEP, and allows determination of the heavy and light chain type of the urinary monoclonal protein. It does not estimate the size of the monoclonal protein and hence is done in conjunction with UPEP. (See",
"    <a class=\"local\" href=\"#H31\">",
"     '24-hour urine protein electrophoresis (UPEP)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The presence of a urinary monoclonal light chain on immunofixation is characterized by a discrete band with reactivity to either kappa or lambda antisera, but not both (",
"    <a class=\"graphic graphic_figure graphicRef75044 \" href=\"mobipreview.htm?42/51/43824\">",
"     figure 8",
"    </a>",
"    ). Two discrete bands with either kappa or lambda antisera (but not both) may be found; this is usually due to the presence of monomers and dimers of the monoclonal light chain protein. However, a discrete band with heavy chain antisera reactivity corresponding to the type of heavy chain present in the patient's serum and coinciding with one of the two light chain bands indicates the presence of a fragment of the intact immunoglobulin (",
"    <a class=\"graphic graphic_figure graphicRef74774 \" href=\"mobipreview.htm?29/55/30576\">",
"     figure 9",
"    </a>",
"    ). This is of no particular clinical relevance.",
"   </p>",
"   <p>",
"    A biclonal gammopathy with one monoclonal protein having a kappa chain and the other having a lambda chain rarely occurs. Occasionally, regularly spaced faint but discrete multiple bands are seen on immunofixation. These restricted bands represent related polyclonal free light chains and are not to be confused with monoclonal light chains. This phenomenon has been described as \"ladder light chain\" or a \"pseudo-oligoclonal pattern\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1965968\">",
"     'Biclonal gammopathy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient has nephrotic syndrome, the presence of a monoclonal light chain strongly suggests either primary amyloidosis (AL) or light chain deposition disease in almost all instances. If UPEP reveals a localized globulin band and immunofixation does not demonstrate a monoclonal light chain, one should suspect the possibility of heavy chain deposition disease. Immunofixation should then be performed with antisera to IgG (gamma heavy chains). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=see_link\">",
"     \"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Theoretically, antisera that recognize only free kappa or free lambda light chains should be used rather than antisera that recognize both free light chains as well as light chains that are part of an intact immunoglobulin. However, such antisera are often either nonspecific or insufficiently potent. In addition, a patient may have an immunoglobulin fragment that free kappa or free lambda antisera do not recognize. Thus, it is advisable to use kappa and lambda antisera that are monospecific and potent and able to recognize both free and combined light chains when performing immunofixation. This is especially important, as some patients have isolated Bence Jones proteinuria with no M-spike in the serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/29,33\">",
"     29,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine immunofixation should be performed at baseline in all patients with a diagnosis of a plasma cell dyscrasia. Immunofixation should be performed in these patients even if the routine urine analysis is negative for protein, 24-hour urine protein concentration is within normal limits, and UPEP of a concentrated urine specimen shows no globulin peak. Immunofixation is sufficiently sensitive to detect a urine M-protein of &ge;0.004",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?9/58/10154/abstract/13\">",
"     13",
"    </a>",
"    ]. Urine immunofixation is subsequently required to assess and document complete response in patients receiving therapy.",
"   </p>",
"   <p>",
"    Urine immunofixation has also been used as a standard test for patients in whom there is clinical suspicion for a monoclonal plasma cell proliferative disorder such as myeloma or primary amyloidosis. The serum free light chain assay can be used as an alternative method. (See",
"    <a class=\"local\" href=\"#H2212928\">",
"     'Serum free light chains'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     EVALUATION OF MONOCLONAL GAMMOPATHIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is of great importance for the physician to be in contact with the laboratory concerning interpretation of these laboratory tests. It is also essential that the laboratory know when the physician suspects primary amyloidosis or a plasma",
"    <span class=\"nowrap\">",
"     cell/lymphocytic",
"    </span>",
"    disorder so that a greater effort can be made for the detection of an M-protein, which may be present in such a low concentration that it is not be detected by routine serum or urine protein electrophoresis, but may be detected by more sensitive techniques (eg, immunofixation or free light chain assay).",
"   </p>",
"   <p>",
"    A search for monoclonal proteins should be undertaken as part of the evaluation of all patients in whom multiple myeloma, Waldenstr&ouml;m macroglobulinemia, primary AL (light chain) amyloidosis, or a related disorder is suspected. This evaluation should also be considered in any patient with an elevated total serum protein or otherwise unexplained signs and symptoms suggestive of the presence of a plasma cell disorder. An initial search for monoclonal proteins usually includes an SPEP, serum immunofixation, 24-hour UPEP, and urine immunofixation. Alternatively, a serum FLC assay may be used instead of the 24-hour UPEP as an initial test. This evaluation of monoclonal gammopathies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23851196\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An M-protein is a monoclonal immunoglobulin secreted by an abnormally expanded clone of plasma cells in an amount that can be detected by immunofixation of serum, urine,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other body fluids or by a serum free light chain assay. The M-protein can be an intact immunoglobulin (ie, containing both heavy and light chains) or can be composed of only light chains or only heavy chains. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of an M-protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of an M-protein indicates an underlying clonal plasma cell or lymphoproliferative disorder (",
"      <a class=\"graphic graphic_table graphicRef70820 \" href=\"mobipreview.htm?43/21/44380\">",
"       table 1",
"      </a>",
"      ). M-proteins may be part of an asymptomatic limited clonal expansion of plasma cells, be a manifestation of a malignancy, or may lead to life-threatening complications even if the clonal expansion that produced the M-protein is limited. The clinician seeing a patient with a monoclonal protein must therefore make the appropriate diagnosis and initiate effective therapy in a timely manner, in order to prevent irreversible organ damage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shortening of life. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clonal size'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analysis of serum for the presence of M-proteins, or for the evaluation of a patient with increased total serum proteins, is classically performed using electrophoretic techniques, supplemented with additional tests for protein quantification and methodologies to determine whether the protein arises from a single clone (ie, monoclonal) (",
"      <a class=\"graphic graphic_table graphicRef70590 \" href=\"mobipreview.htm?27/29/28124\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Serum protein electrophoresis (SPEP) separates serum proteins and allows for the detection and quantification of an M-protein in the blood. The M-protein usually presents as a single narrow peak, like a church spire, in the gamma, beta, or alpha-2 region of the densitometer tracing or as a dense, discrete band on the agarose gel (",
"      <a class=\"graphic graphic_figure graphicRef67685 graphicRef74787 \" href=\"mobipreview.htm?14/5/14420\">",
"       figure 2A-B",
"      </a>",
"      ). In contrast, a broad-based peak or band, usually of gamma mobility, suggests a polyclonal increase in immunoglobulins, most often due to an infectious, inflammatory, or reactive process (",
"      <a class=\"graphic graphic_figure graphicRef74708 graphicRef74787 \" href=\"mobipreview.htm?11/46/12004\">",
"       figure 2B, 2D",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Serum protein electrophoresis (SPEP)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum immunofixation uses antibodies directed against heavy chain and light chain components to differentiate a monoclonal from a polyclonal increase in immunoglobulins and to determine the type of immunoglobulin involved (eg, IgG kappa). An M-protein is characterized on immunofixation by the combined presence of a sharp, well-defined band associated with a single heavy-chain class and a sharp and well-defined band with similar mobility characteristics which reacts with either kappa or lambda light chain antisera, but not both (",
"      <a class=\"graphic graphic_figure graphicRef55916 \" href=\"mobipreview.htm?4/39/4735\">",
"       figure 4",
"      </a>",
"      ). These tests do not quantify the M-protein. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Serum immunofixation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serum free light chain (FLC) assay is an antibody-based system that can detect low concentrations of monoclonal free light chains (ie, kappa or lambda) in the serum. This assay is more sensitive for the detection of light chains than urine immunofixation; however, results may be affected by the presence of renal failure. (See",
"      <a class=\"local\" href=\"#H2212928\">",
"       'Serum free light chains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quantitative immunoglobulins can detect hypogammaglobulinemia and hypergammaglobulinemia, but does not allow an assessment of monoclonality. Increased levels can be due to polyclonal or monoclonal elevations; clonality needs to be established using SPEP and immunofixation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Quantitation of immunoglobulins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although dipsticks are used in many laboratories to screen for the presence of protein in the urine, these tests are often unable to detect Bence Jones protein (free kappa or lambda light chains). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link&amp;anchor=H7#H7\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\", section on 'Standard urine dipstick'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      A 24-hour urine protein electrophoresis (UPEP) uses electrophoresis to separate urine proteins and allows for the detection and quantification of an M-protein in the urine. Urine immunofixation must be performed in conjunction with the UPEP in order to differentiate a monoclonal from a polyclonal increase in immunoglobulins and to determine the type of light chain involved. (See",
"      <a class=\"local\" href=\"#H31\">",
"       '24-hour urine protein electrophoresis (UPEP)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H33\">",
"       'Urine immunofixation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A search for monoclonal proteins should be undertaken as part of the evaluation of all patients in whom multiple myeloma, Waldenstr&ouml;m macroglobulinemia, primary AL (light chain) amyloidosis, or a related disorder is suspected. This evaluation should also be considered in any patient with an elevated total serum protein or otherwise unexplained signs and symptoms suggestive of the presence of a plasma cell disorder. An initial search for monoclonal proteins usually includes an SPEP, serum immunofixation, routine urinalysis, 24-hour UPEP, and urine immunofixation. Alternatively, a serum FLC assay may be used instead of the 24-hour UPEP as a screening test. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Evaluation of monoclonal gammopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum viscosity should be performed in any patient with a monoclonal gammopathy and signs and symptoms suggesting the hyperviscosity syndrome and for all patients with a monoclonal IgM protein spike &gt;4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or an IgA or IgG protein spike &gt;6",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2213249\">",
"       'Serum viscosity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Katzmann JA, Kyle RA. Immunochemical characterization of immunoglobulins in serum, urine, and cerebrospinal fluid. In: Manual of Molecular and Clinical Laboratory Immunology, 7th ed, Detrick B (Ed), American Society for Microbiology Press, Washington, DC 2006. p.88.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/2\">",
"      Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009; 147:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/3\">",
"      Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/4\">",
"      Berth M, Delanghe J. Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. Acta Clin Belg 2004; 59:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/5\">",
"      Smogorzewska A, Flood JG, Long WH, Dighe AS. Paraprotein interference in automated chemistry analyzers. Clin Chem 2004; 50:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/6\">",
"      Tsai LY, Tsai SM, Lee SC, Liu SF. Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. Clin Chim Acta 2005; 358:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/7\">",
"      Pantanowitz L, Horowitz GL, Upalakalin JN, Beckwith BA. Artifactual hyperbilirubinemia due to paraprotein interference. Arch Pathol Lab Med 2003; 127:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/8\">",
"      Murali MR, Kratz A, Finberg KE. Case records of the Massachusetts General Hospital. Case 40-2006. A 64-year-old man with anemia and a low level of HDL cholesterol. N Engl J Med 2006; 355:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/9\">",
"      Krish P, Jhaveri KD. The Case  Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia. Kidney Int 2012; 81:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/10\">",
"      Alyanakian MA, Taes Y, Bensa&iuml;d M, et al. Monoclonal immunoglobulin with antitransferrin activity: A rare cause of hypersideremia with increased transferrin saturation. Blood 2007; 109:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/11\">",
"      Katzmann JA, Clark R, Wiegert E, et al. Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. Electrophoresis 1997; 18:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/12\">",
"      Katzmann JA, Clark R, Sanders E, et al. Prospective study of serum protein capillary zone electrophoresis and immunotyping of monoclonal proteins by immunosubtraction. Am J Clin Pathol 1998; 110:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/13\">",
"      International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/14\">",
"      Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med 1981; 71:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/15\">",
"      Dispenzieri A, Gertz MA, Therneau TM, Kyle RA. Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 2001; 76:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/16\">",
"      De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/17\">",
"      Amara S, Dezube BJ, Cooley TP, et al. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis 2006; 43:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/18\">",
"      Yee TT, Murphy K, Johnson M, et al. Multiple myeloma and human immunodeficiency virus-1 (HIV-1) infection. Am J Hematol 2001; 66:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/19\">",
"      Dezube BJ, Aboulafia DM, Pantanowitz L. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read 2004; 14:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/20\">",
"      Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/21\">",
"      Pola V, Tich&yacute; M. [Bisalbuminemia. Critical review and report of a case of an acquired form in a myeloma patient]. Folia Haematol Int Mag Klin Morphol Blutforsch 1985; 112:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/22\">",
"      Rambaud JC, Halphen M, Galian A, Tsapis A. Immunoproliferative small intestinal disease (IPSID): relationships with alpha-chain disease and \"Mediterranean\" lymphomas. Springer Semin Immunopathol 1990; 12:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/23\">",
"      Seligmann M, Mihaesco E, Preud'homme JL, et al. Heavy chain diseases: current findings and concepts. Immunol Rev 1979; 48:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/24\">",
"      Fermand JP, Brouet JC. Heavy-chain diseases. Hematol Oncol Clin North Am 1999; 13:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/25\">",
"      Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/26\">",
"      Wahner-Roedler DL, Kyle RA. Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. Am J Hematol 1992; 40:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/27\">",
"      Fermand JP, Brouet JC, Danon F, Seligmann M. Gamma heavy chain \"disease\": heterogeneity of the clinicopathologic features. Report of 16 cases and review of the literature. Medicine (Baltimore) 1989; 68:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/28\">",
"      Wahner-Roedler DL, Witzig TE, Loehrer LL, Kyle RA. Gamma-heavy chain disease: review of 23 cases. Medicine (Baltimore) 2003; 82:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/29\">",
"      Kyle RA, Greipp PR. \"Idiopathic\" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982; 306:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/30\">",
"      Grosbois B, J&eacute;go P, de Rosa H, et al. [Triclonal gammopathy and malignant immunoproliferative syndrome]. Rev Med Interne 1997; 18:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/31\">",
"      Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/32\">",
"      Nowrousian MR, Brandhorst D, Sammet C, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11:8706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/33\">",
"      Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/34\">",
"      Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/35\">",
"      Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008; 141:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/36\">",
"      Abraham RS, Katzmann JA, Clark RJ, et al. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003; 119:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/37\">",
"      Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/38\">",
"      Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/39\">",
"      van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/40\">",
"      Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/41\">",
"      Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009; 131:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/42\">",
"      Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/43\">",
"      Vermeersch P, Van Hoovels L, Delforge M, et al. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol 2008; 143:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/44\">",
"      Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008; 93:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/45\">",
"      Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995; 10:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/46\">",
"      Riches PG, Sheldon J, Smith AM, Hobbs JR. Overestimation of monoclonal immunoglobulin by immunochemical methods. Ann Clin Biochem 1991; 28 ( Pt 3):253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/47\">",
"      Sinclair D, Ballantyne F, Shanley S, et al. Estimation of paraproteins by immunoturbidimetry and electrophoresis followed by scanning densitometry. Ann Clin Biochem 1990; 27 ( Pt 4):335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?9/58/10154/abstract/48\">",
"      Harrison HH. The \"ladder light chain\" or \"pseudo-oligoclonal\" pattern in urinary immunofixation electrophoresis (IFE) studies: a distinctive IFE pattern and an explanatory hypothesis relating it to free polyclonal light chains. Clin Chem 1991; 37:1559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6655 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-C266496ECC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10154=[""].join("\n");
var outline_f9_58_10154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23851196\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF AN M-PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL RELEVANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clonal size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interference with laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANALYSIS OF SERUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serum protein electrophoresis (SPEP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Monoclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1965968\">",
"      - Biclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Polyclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypogammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2213735\">",
"      - Other SPEP patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - False negative results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - False positive results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serum immunofixation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2212928\">",
"      Serum free light chains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2212935\">",
"      - Indications and uses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2212942\">",
"      - Use in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2213249\">",
"      Serum viscosity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Quantitation of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ANALYSIS OF URINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      24-hour urine protein electrophoresis (UPEP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Urine immunofixation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      EVALUATION OF MONOCLONAL GAMMOPATHIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23851196\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6655|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/2/1071\" title=\"figure 1\">",
"      Antibody structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/3/21566\" title=\"figure 2A\">",
"      Monoclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/32/42497\" title=\"figure 2B\">",
"      Normal SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/1/29727\" title=\"figure 2C\">",
"      Biclonal gammopathy on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/4/18510\" title=\"figure 2D\">",
"      Polyclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/23/11638\" title=\"figure 3\">",
"      Biclonal pattern immunofix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/39/4735\" title=\"figure 4\">",
"      Monoclonal pattern immunofixation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/41/25238\" title=\"figure 5\">",
"      Triclonal pattern immunofix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/57/1951\" title=\"figure 6\">",
"      Free light chains serum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7503\" title=\"figure 7\">",
"      Bence Jones protein UPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43824\" title=\"figure 8\">",
"      Bence Jones protein immunofix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/55/30576\" title=\"figure 9\">",
"      Urinary IgG fragment immunofix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6655|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/21/44380\" title=\"table 1\">",
"      Causes monoclonal gammopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/7/30844\" title=\"table 2\">",
"      Pseudorenal panel abnormalities paraproteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/29/28124\" title=\"table 3\">",
"      Recognizing M-protein in serum and urine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/15/7418?source=related_link\">",
"      Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/47/762?source=related_link\">",
"      Epidemiology, pathogenesis, clinical manifestations and diagnosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/14/35049?source=related_link\">",
"      POEMS syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22551?source=related_link\">",
"      Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12470?source=related_link\">",
"      The heavy chain diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37626?source=related_link\">",
"      Treatment and prognosis of Waldenstr&ouml;m macroglobulinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_58_10155="Motor exam score";
var content_f9_58_10155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Motor function score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        No contraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Flicker or trace of contraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Active movement with gravity eliminated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Active movement against gravity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Active movement against gravity and resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        Normal power",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brain Journal. Aids to the Examination of the Peripheral Nervous System, WB Saunders, 2000. Illustration used with permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10155=[""].join("\n");
var outline_f9_58_10155=null;
var title_f9_58_10156="Degree of virulence K pneum";
var content_f9_58_10156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determination of the degree of virulence conferred by K. pneumoniae",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measurement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Virulence for mice",
"       </td>",
"       <td rowspan=\"4\">",
"        Intraperitoneal injection of bacterial suspension to observe the death rate of mice",
"       </td>",
"       <td rowspan=\"4\">",
"        50 percent lethal dose: LD",
"        <sub>",
"         50",
"        </sub>",
"        (CFU)",
"       </td>",
"       <td>",
"        Highly virulent: &le;10",
"        <sup>",
"         3",
"        </sup>",
"        CFU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate virulence: 10",
"        <sup>",
"         4",
"        </sup>",
"        -10",
"        <sup>",
"         5",
"        </sup>",
"        CFU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low virulence: 10",
"        <sup>",
"         6",
"        </sup>",
"        -10",
"        <sup>",
"         7",
"        </sup>",
"        CFU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No virulence: &ge;10",
"        <sup>",
"         8",
"        </sup>",
"        CFU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Phagocytosis: macrophage adherence assay",
"       </td>",
"       <td rowspan=\"2\">",
"        Human or mouse macrophage are mixed with bacteria to quantify ingesting cells",
"       </td>",
"       <td rowspan=\"2\">",
"        Percent of 100 macrophages containing attached or ingested bacteria",
"       </td>",
"       <td>",
"        Low-level binding: 2 to 3 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High-level binding: 8 to 13 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum resistance assay",
"       </td>",
"       <td>",
"        Nonimmune human serum are incubated with bacteria to determine colony count at serial hours",
"       </td>",
"       <td>",
"        Survival curve (the average survival ratio against time)",
"       </td>",
"       <td>",
"        Bacteria that actively proliferate in serum are resistant to serum killing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whole blood resistance",
"       </td>",
"       <td>",
"        Incubate fresh mouse blood with bacterial suspension",
"       </td>",
"       <td>",
"        Survival of bacteria in blood",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10156=[""].join("\n");
var outline_f9_58_10156=null;
var title_f9_58_10157="Management of short bowel syndrome in children";
var content_f9_58_10157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of short bowel syndrome in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical issue",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Assess likelihood of resuming an oral diet",
"       </td>",
"       <td>",
"        Increased likelihood of resuming oral diet&nbsp;if the colon is&nbsp;intact, or if the remaining bowel segment is long.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May take months to years, depending on the pace of intestinal adaptation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Anticipate consequences based upon remaining intestinal segments",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         The proximal small intestine is normally responsible for absorption of proteins and carbohydrates. However, after adaptation the ileum is able to perform these functions.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         The distal ileum is responsible for absorption of vitamin B12 and bile salts. In general, in adults:",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp;&nbsp; &lt;100 cm of distal ileum resected causes moderate bile salt malabsorption, so that&nbsp;bile salts&nbsp;enter the colon and cause secretory diarrhea (choleretic enteropathy)",
"        </p>",
"        <p>",
"         &nbsp;&nbsp;&nbsp; &gt;100 cm of distal ileum resected&nbsp;causes&nbsp;severe bile salt malabsorption, leading to&nbsp;an inadequate bile salt pool and&nbsp;fat malabsorption.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of the colon in combination with extensive small bowel resection&nbsp;is poorly tolerated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Early management",
"       </td>",
"       <td>",
"        Fluid and electrolyte replacement predominates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Begin enteral feeding once patient stabilizes. Initially use breast milk or&nbsp;a hypoallergenic (semi-elemental)&nbsp;formula if the patient is younger than one year of age.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antidiarrheal&nbsp;(antimotility) agents may&nbsp;be useful,&nbsp;unless bacterial overgrowth is present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Enteral nutrition",
"       </td>",
"       <td>",
"        Continuous enteral feeding or small frequent feedings is preferred. Continuous feeding takes full advantage of absorptive surface area and may facilitate intestinal adaption.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advance feeds slowly and taper parenteral nutrition. We initiate feeds by providing approximately 5 percent of total daily caloric need,&nbsp;then make&nbsp;slow incremental advances every three to seven days as tolerated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: calibri,sans-serif; font-size: 11pt;\">",
"         The most useful index of carbohydrate malabsorption is stool output. Carbohydrate malabsorption can also be confirmed by testing the stool for glucose (Clinitest tablet).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral feeding",
"       </td>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         To prevent the development of feeding aversion, infants should be fed breast milk or formula by mouth, and transitioned to solids at an age-appropriate time, even only small amounts of feeds can be given by this route.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric acid hypersecretion",
"       </td>",
"       <td>",
"        H2 blocker or PPI. The efficacy and dosing can be determined by measuring gastric pH and aiming for pH &gt;7.&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial overgrowth&nbsp;",
"       </td>",
"       <td>",
"        Monitor D-lactate level, urine indicans, and glucose breath hydrogen. If positive, treat with low-dose rotating antibiotic therapy.&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choleretic enteropathy",
"       </td>",
"       <td>",
"        Patient is at risk if terminal ileum was resected. Use bile salt sequestering agents.&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat soluble vitamin malabsorption",
"       </td>",
"       <td>",
"        Monitor every three months, and replace as needed. Extra vigilance is needed during the transition off of parenteral nutrition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin and mineral malabsorption (potassium, chloride, magnesium, calcium, zinc, iron, selenium, and vitamin B12 )",
"       </td>",
"       <td>",
"        Monitor every three months, and replace as needed. Extra vigilance is needed during the transition off of parenteral nutrition.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H2 blocker: histamine H2 receptor antagonist; PPI: proton pump inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10157=[""].join("\n");
var outline_f9_58_10157=null;
var title_f9_58_10158="Nasal stenting";
var content_f9_58_10158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal stenting after transnasal choanal atresia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 140px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nasal stenting after transnasal choanal atresia repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10158=[""].join("\n");
var outline_f9_58_10158=null;
var title_f9_58_10159="Atenolol dose in angina";
var content_f9_58_10159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Dose-dependence of efficacy of atenolol in stable angina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of different daily doses of atenolol (25, 50, 100, and 200 mg) in patients with stable angina. There was a tendency toward increasing efficacy with increasing dose. Only the 100 and 200 mg doses were significantly effective at trough levels with respect to exercise time and ST depression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Jackson G, Schwartz J, Kates RE, et al. Circulation 1980; 61:555.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_58_10159=[""].join("\n");
var outline_f9_58_10159=null;
        